131 related articles for article (PubMed ID: 23546174)
1. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo.
Zhang LL; Zhang J; Shen L; Xu XM; Yu HG
Mol Med Rep; 2013 May; 7(5):1387-90. PubMed ID: 23546174
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
3. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
4. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
[TBL] [Abstract][Full Text] [Related]
5. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
6. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
7. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.
Kim MJ; Nam HJ; Kim HP; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Cancer Lett; 2013 Jul; 335(1):145-52. PubMed ID: 23402820
[TBL] [Abstract][Full Text] [Related]
8. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax.
Kim CW; Lu JN; Go SI; Jung JH; Yi SM; Jeong JH; Hah YS; Han MS; Park JW; Lee WS; Min YJ
Int J Oncol; 2013 Nov; 43(5):1495-502. PubMed ID: 23970333
[TBL] [Abstract][Full Text] [Related]
9. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells.
Xu W; Chen GS; Shao Y; Li XL; Xu HC; Zhang H; Zhu GQ; Zhou YC; He XP; Sun WH
Cancer Lett; 2013 May; 332(1):11-8. PubMed ID: 23376640
[TBL] [Abstract][Full Text] [Related]
10. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells.
Lin Y; Wang Z; Liu L; Chen L
Lung Cancer; 2011 Mar; 71(3):291-7. PubMed ID: 20599289
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
12. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin.
Hu W; Jin P; Liu W
Cell Physiol Biochem; 2016; 38(3):1199-208. PubMed ID: 26982182
[TBL] [Abstract][Full Text] [Related]
13. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
14. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
15. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.
Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin.
Mao Z; Bian G; Sheng W; He S; Yang J; Dong X
Oncol Rep; 2013 Nov; 30(5):2288-96. PubMed ID: 23982423
[TBL] [Abstract][Full Text] [Related]
17. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway.
Zhou D; Liu W; Liang S; Sun B; Liu A; Cui Z; Han X; Yuan L
Cancer Med; 2018 Apr; 7(4):1369-1383. PubMed ID: 29522284
[TBL] [Abstract][Full Text] [Related]
18. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
19. Ginkgolic acid (GA) suppresses gastric cancer growth by inducing apoptosis and suppressing STAT3/JAK2 signaling regulated by ROS.
Liang JR; Yang H
Biomed Pharmacother; 2020 May; 125():109585. PubMed ID: 32106377
[TBL] [Abstract][Full Text] [Related]
20. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]